Champions Oncology Announces A Multi-Year Agreement And Strategic Collaboration With BioVolume To Transform Reproducibility In Preclinical Oncology Efficacy Studies
Portfolio Pulse from Happy Mohamed
Champions Oncology, Inc. (NASDAQ:CSBR) has announced a multi-year agreement with BioVolume to adopt its 3D imaging and thermal technology for capturing efficacy results in preclinical oncology studies. The technology will be incorporated into Champions Oncology's preclinical offerings, aiming to improve accuracy, reduce variability, and generate reliable insights for oncology drug development programs. BioVolume's technology provides a digital record of preclinical efficacy, offering a statistically significant reduction in variability compared to manual measurement methods.
August 01, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Champions Oncology's partnership with BioVolume to adopt its 3D imaging and thermal technology could enhance the company's preclinical offerings and improve the reliability of its oncology drug development programs. This could potentially attract more clients and increase revenues.
The adoption of BioVolume's technology could significantly improve the accuracy and reliability of Champions Oncology's preclinical oncology studies. This could potentially attract more clients seeking reliable and accurate preclinical research services, leading to increased revenues for the company. Therefore, the news is likely to have a positive impact on CSBR's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100